{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:22Z","timestamp":1792788502281,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ruprecht-Karls-Universit\u00e4t Heidelberg","id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fibroblast activation protein inhibitor (FAPI)-targeted positron emission tomography (PET) has emerged as a promising imaging approach in soft tissue sarcomas (STS), whereas magnetic resonance imaging (MRI) remains the diagnostic standard. We evaluated integrated [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga\u2011FAPI\u201146 PET\/MRI including maximum standard uptake value (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ), diffusion-weighted imaging, apparent diffusion coefficient (ADC), and contrast-enhanced sequences compared to FAP expression in immunohistochemistry for tumor assessment in high-grade STS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga\u2011FAPI\u201146 PET\/MRI examinations from 9 patients were included, of which 4 were follow-up scans after therapy. All STS showed distinct FAPI uptake (median SUV\n                      <jats:sub>max<\/jats:sub>\n                      8.4; range 2.9\u201333). Mean SUV\n                      <jats:sub>max<\/jats:sub>\n                      was 13 (2.9\u201333) for G2 and 8.4 (7.5\u20138.4) for G3 tumors. Neither SUV\n                      <jats:sub>max<\/jats:sub>\n                      (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.196) nor ADC (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.895) differentiated between FNCLCC Grade 2 and Grade 3. A significant inverse correlation was observed between ADC\n                      <jats:sub>mean<\/jats:sub>\n                      and SUV\n                      <jats:sub>max<\/jats:sub>\n                      (Spearman\u2019s \u03c1 = \u22120.70, 95% CI: \u22120.93 to \u2212\u20090.07,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.035). Immunohistochemistry demonstrated positive FAP expression in 4 of 9 patients, with significantly higher SUV\n                      <jats:sub>max<\/jats:sub>\n                      in FAP-positive vs. negative tumors in immunohistochemistry (17.7 vs. 6.4;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.047). High concordance of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 uptake and contrast enhancement was observed. Treatment responders showed marked reductions in SUV\n                      <jats:sub>max<\/jats:sub>\n                      (40\u201370%) and increased ADC without significant changes in tumor size.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this exploratory pilot study, [68Ga]Ga-FAPI-46 PET\/MRI provided complementary functional information in high-grade STS. Although no correlation with grading was observed either using SUVmax or ADC, a significant inverse correlation between ADCmean and SUVmax was identified within this cohort. Preliminary observations regarding treatment monitoring suggested that early changes in tracer uptake and ADC may reflect treatment-related changes, however, these findings were derived from a small pilot cohort. Larger prospective studies are required to validate these observations and to further define the potential role of [68Ga]Ga-FAPI-46 PET\/MRI in treatment monitoring and response assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01517-6","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:25:32Z","timestamp":1790069132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation of apparent diffusion coefficient, FAP expression in IHC and [68Ga]Ga\u2011FAPI\u201146 uptake using integrated PET\/MRI in high-grade soft tissue sarcoma: initial exploratory results"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9728-2494","authenticated-orcid":false,"given":"Madelaine","family":"Hettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franka","family":"Menge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"N\u00f6renberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Sch\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hinterberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"W\u00e4ngler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"W\u00e4ngler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Rudolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcll\u00fc","family":"Davarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cieslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina L.","family":"Cotarelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Harbr\u00fccker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rei\u00dffelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freba","family":"Grawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"1","key":"1517_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12889-018-5131-4","volume":"18","author":"M Ressing","year":"2018","unstructured":"Ressing M, et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health. 2018;18(1):235.","journal-title":"BMC Public Health"},{"issue":"5","key":"1517_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","volume":"17","author":"D Callegaro","year":"2016","unstructured":"Callegaro D, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671\u201380.","journal-title":"Lancet Oncol"},{"issue":"Supplement4","key":"1517_CR3","doi-asserted-by":"publisher","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, et al. Soft tissue and visceral sarcomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement4):iv51\u201367.","journal-title":"Ann Oncol"},{"issue":"12","key":"1517_CR4","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1007\/s00330-004-2431-0","volume":"14","author":"JLMA Gielen","year":"2004","unstructured":"Gielen JLMA, et al. Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. Eur Radiol. 2004;14(12):2320\u201330.","journal-title":"Eur Radiol"},{"issue":"7","key":"1517_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/PAS.0000000000000867","volume":"41","author":"N Schneider","year":"2017","unstructured":"Schneider N, et al. The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues: Implications for Treatment and Prognosis. Am J Surg Pathol. 2017;41(7):923\u201331.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1517_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/bjs.11064","volume":"106","author":"LM Almond","year":"2019","unstructured":"Almond LM, et al. Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma. Br J Surg. 2019;106(4):395\u2013403.","journal-title":"Br J Surg"},{"issue":"3","key":"1517_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1148\/radiol.2019181659","volume":"291","author":"A Cromb\u00e9","year":"2019","unstructured":"Cromb\u00e9 A, et al. Soft-Tissue Sarcomas: Assessment of MRI Features Correlating with Histologic Grade and Patient Outcome. Radiology. 2019;291(3):710\u201321.","journal-title":"Radiology"},{"issue":"8","key":"1517_CR8","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1007\/s00330-018-5845-9","volume":"29","author":"A Chhabra","year":"2019","unstructured":"Chhabra A, et al. Conventional MR and diffusion-weighted imaging of musculoskeletal soft tissue malignancy: correlation with histologic grading. Eur Radiol. 2019;29(8):4485\u201394.","journal-title":"Eur Radiol"},{"key":"1517_CR9","doi-asserted-by":"publisher","first-page":"111548","DOI":"10.1016\/j.ejrad.2024.111548","volume":"177","author":"F Schmitz","year":"2024","unstructured":"Schmitz F, Sedaghat S. Inferring malignancy grade of soft tissue sarcomas from magnetic resonance imaging features: A systematic review. Eur J Radiol. 2024;177:111548.","journal-title":"Eur J Radiol"},{"issue":"17","key":"1517_CR10","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.3390\/cancers14174331","volume":"14","author":"M Hettler","year":"2022","unstructured":"Hettler M, et al. Comparing Apparent Diffusion Coefficient and FNCLCC Grading to Improve Pretreatment Grading of Soft Tissue Sarcoma-A Translational Feasibility Study on Fusion Imaging. Cancers (Basel). 2022;14(17):4431.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1517_CR11","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.3390\/jcm9082549","volume":"9","author":"A Annovazzi","year":"2020","unstructured":"Annovazzi A, et al. Diagnostic and Clinical Impact of 18F-FDG PET\/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center. J Clin Med. 2020;9(8):2549.","journal-title":"J Clin Med"},{"issue":"4","key":"1517_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1053\/j.semnuclmed.2017.02.009","volume":"47","author":"RV Parghane","year":"2017","unstructured":"Parghane RV, Basu S. Dual\u2013time point 18 F-FDG-PET and PET\/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations. Semin Nucl Med. 2017;47(4):373\u201391.","journal-title":"Semin Nucl Med"},{"issue":"8","key":"1517_CR13","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s00259-022-05700-4","volume":"49","author":"B Gu","year":"2022","unstructured":"Gu B, et al. Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET\/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging. 2022;49(8):2889\u2013901.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1517_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2559.2009.03399.x","volume":"55","author":"O Dohi","year":"2009","unstructured":"Dohi O, et al. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase\u2010IV in human bone and soft tissue tumours. Histopathology. 2009;55(4):432\u201340.","journal-title":"Histopathology"},{"issue":"9","key":"1517_CR15","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.85.9.3110","volume":"85","author":"WJ Rettig","year":"1988","unstructured":"Rettig WJ, et al. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci. 1988;85(9):3110\u20134.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"1517_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1470-2045(25)00299-2","volume":"26","author":"KM Pabst","year":"2025","unstructured":"Pabst KM, et al. [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial. Lancet Oncol. 2025;26(9):1204\u201314.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1517_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, et al. 68Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019;60(3):386\u201392.","journal-title":"J Nucl Med"},{"issue":"6","key":"1517_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, et al. 68-Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"issue":"12","key":"1517_CR19","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan MJ, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci. 1994;91(12):5657\u201361.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1517_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2967\/jnumed.121.262096","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler L, et al. 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial. J Nucl Med. 2022;63(1):89\u201395.","journal-title":"J Nucl Med"},{"issue":"6","key":"1517_CR21","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.123.267248","volume":"65","author":"H Lanzafame","year":"2024","unstructured":"Lanzafame H, et al. 68Ga-Fibroblast Activation Protein Inhibitor PET\/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy. J Nucl Med. 2024;65(6):880\u20137.","journal-title":"J Nucl Med"},{"issue":"6","key":"1517_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/1078-0432.CCR-06-1746","volume":"13","author":"LR Henry","year":"2007","unstructured":"Henry LR, et al. Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer. Clin Cancer Res. 2007;13(6):1736\u201341.","journal-title":"Clin Cancer Res"},{"key":"1517_CR23","doi-asserted-by":"crossref","unstructured":"Abdulrahman M, et al. Exploring the Diagnostic and Theranostic Role of FAPI PET in Soft Tissue Sarcoma: A Systematic Review. Nuclear Medicine and Molecular Imaging; 2025.","DOI":"10.1007\/s13139-025-00936-y"},{"issue":"8","key":"1517_CR24","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1517_CR25","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1007\/s00259-021-05374-4","volume":"48","author":"SA Koerber","year":"2021","unstructured":"Koerber SA, et al. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48(12):3918\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1517_CR26","doi-asserted-by":"publisher","first-page":"e15478","DOI":"10.5812\/iranjradiol.15478v2","volume":"12","author":"Y Pekcevik","year":"2015","unstructured":"Pekcevik Y, Onur M, Kahya, Kaya A. Characterization of Soft Tissue Tumors by Diffusion-Weighted Imaging. Iran J Radiol. 2015;12(3):e15478.","journal-title":"Iran J Radiol"},{"issue":"2","key":"1517_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00256-015-2302-6","volume":"45","author":"PA Gondim Teixeira","year":"2016","unstructured":"Gondim Teixeira PA, et al. Diffusion-weighted magnetic resonance imaging for the initial characterization of non-fatty soft tissue tumors: correlation between T2 signal intensity and ADC values. Skeletal Radiol. 2016;45(2):263\u201371.","journal-title":"Skeletal Radiol"},{"issue":"1","key":"1517_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11547-011-0709-2","volume":"117","author":"A Razek","year":"2012","unstructured":"Razek A, et al. Assessment of soft tissue tumours of the extremities with diffusion echoplanar MR imaging. Radiol Med. 2012;117(1):96\u2013101.","journal-title":"Radiol Med"},{"key":"1517_CR29","doi-asserted-by":"publisher","first-page":"153562","DOI":"10.1016\/j.prp.2021.153562","volume":"225","author":"I Machado","year":"2021","unstructured":"Machado I, et al. Ki-67 immunoexpression and radiological assessment of necrosis improves accuracy of conventional and modified core biopsy systems in predicting the final grade assigned to adult-soft tissue sarcomas. An international collaborative study. Pathol Res Pract. 2021;225:153562.","journal-title":"Pathol Res Pract"},{"issue":"12","key":"1517_CR30","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.acra.2022.03.009","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Diagnostic Performance of Dynamic Contrast-Enhanced MRI and 18F-FDG PET\/CT for Evaluation of Soft Tissue Tumors and Correlation with Pathology Parameters. Acad Radiol. 2022;29(12):1842\u201351.","journal-title":"Acad Radiol"},{"issue":"9","key":"1517_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.2967\/jnumed.125.269572","volume":"66","author":"H Lanzafame","year":"2025","unstructured":"Lanzafame H, et al. 90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors. J Nucl Med. 2025;66(9):1378\u201384.","journal-title":"J Nucl Med"},{"issue":"1","key":"1517_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52(1):237\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1517_CR33","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/RLU.0000000000005255","volume":"49","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, et al. First Experience of Radionuclide Therapy With 177Lu-FAPI-2286 in a Patient With Metastatic Mediastinal Sarcoma. Clin Nucl Med. 2024;49(7):e334\u20137.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"1517_CR34","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi M, et al. Feasibility and Therapeutic Potential of 177Lu\u2013Fibroblast Activation Protein Inhibitor\u201346 for Patients With Relapsed or Refractory Cancers. Clin Nucl Med. 2021;46(11):e523\u201330.","journal-title":"Clin Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01517-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:40:07Z","timestamp":1790070007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01517-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01517-6","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective analysis of the data was approved by the local ethics committee of Heidelberg University (EK II 2023-886-AF 11). The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and its later amendments. Written informed consent for participation was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of study results and the images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"137"}}